No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Biotechnology
SUSMED,Inc. develops and sells therapeutic applications in Japan. It operates through DTx product business, and DTx platform business segments. The company develops smartphone based digital therapeutics applications for diseases with insomnia, breast cancer, and kidney disease. It also develops and sells development platform for therapeutic apps and clinical trial systems. In addition, the company offers medical data analysis and consulting services. The company was incorporated in 2015 and is headquartered in Tokyo, Japan.
www.susmed.co.jpNo one on the platform currently holds 4263.T.
No tracked institution reports a position in 4263.T as of their last filing.
No one on the platform has traded 4263.T yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| Rev. Growth % | 7.4% | 33.9% | ||||
| Profit Margin % | -77.0% | -65.8% | ||||
| Free Cash Flow Margin % | -110.3% | -63.1% | ||||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2027 | $1.1B | +35.5% | $-8.90 | $-8.90–$-8.90 | — | 1 |
| 2028 | $1.4B | +35.2% | $2.20 | $2.20–$2.20 | — | 1 |
| 2029 | $2.1B | +47.9% | $25.80 | $25.80–$25.80 | — | 1 |
| 2030 | $3.3B | +57.9% | $70.00 | $70.00–$70.00 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| 4263.TSUSMED,Inc. | $422.00 | -0.94% | $7.1B | — |
| 3649.TFINDEX Inc. | $915.00 | +4.57% | $22.3B | — |
| 366A.TWellness Communications Corporation | $1143.00 | -0.09% | $14.2B | — |
| 3902.TMedical Data Vision Co., Ltd. | $1684.00 | +0.00% | $63.8B | — |
| 4320.TCE Holdings Co., Ltd. | $1645.00 | -0.18% | $27.4B | — |
| 4350.TMedical System Network Co., Ltd. | $505.00 | +1.00% | $14.8B |
Source: Financial Modeling Prep · peers by sector/industry
| — |
| 4575.TCanBas Co., Ltd. | $735.00 | -0.54% | $14.5B | — |